Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
Clinical trial NCT04797806 · UNKNOWN
Trial details
- NCT number
- NCT04797806
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-12
- Primary completion
- 2022-04-30
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.